How India Exports Meloxicam to the World

In the United States, meloxicam is approved for various indications, including the treatment of osteoarthritis and rheumatoid arthritis. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for meloxicam, indicating a competitive generic market. Notably, on August 11, 2005, the FDA approved Mobic (meloxicam) for the relief of signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients aged two years and older. This approval was granted to Avondale Pharmaceuticals, with orphan drug exclusivity expiring on August 11, 2012.

The substantial number of approved ANDAs reflects a well-established regulatory pathway for meloxicam in the U.S. market. The presence of 277 active Indian exporters underscores India's significant role in supplying meloxicam to the United States.

In the European Union, meloxicam has been authorized for both human and veterinary use. For instance, Zynrelef, a combination of bupivacaine and meloxicam, received EU marketing authorization on September 24, 2020, for treating postoperative pain. However, this authorization was withdrawn on October 5, 2023, at the request of the marketing authorization holder, Heron Therapeutics, B.V., due to commercial reasons. (ema.europa.eu)

In the United Kingdom, meloxicam is authorized for veterinary use. For example, Meloxicam Ceva 0.5 mg/ml Oral Suspension for Cats was authorized on June 12, 2024, under the national authorization route. (vmd.defra.gov.uk)

Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for manufacturers exporting to these markets.

Meloxicam is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in global healthcare. It is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, meloxicam is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates its price to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for exporting meloxicam formulations.

The primary patents for meloxicam have expired, leading to a competitive generic market globally. This has facilitated the entry of multiple manufacturers, including Indian exporters, into international markets.

In October 2023, the European Commission withdrew the marketing authorization for Zynrelef (bupivacaine/meloxicam) in the EU at the request of Heron Therapeutics, B.V., due to commercial reasons. (ema.europa.eu)

In June 2024, the UK authorized Meloxicam Ceva 0.5 mg/ml Oral Suspension for Cats for veterinary use, reflecting ongoing regulatory activities in the veterinary sector. (vmd.defra.gov.uk)

These developments highlight the dynamic regulatory landscape for meloxicam, necessitating continuous monitoring by stakeholders.

India's pharmaceutical industry, including the production of Meloxicam, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's APIs and KSMs are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and regulatory changes in China.

In response to this dependency, the Indian government has initiated measures to bolster domestic API production. Notably, in October 2024, two greenfield plants were inaugurated under the Production Linked Incentive (PLI) scheme, aiming to manufacture critical molecules such as Penicillin G, 6-APA, and Clavulanic Acid. These efforts are intended to reduce import dependence by half for essential pharmaceutical ingredients. However, the effectiveness of these initiatives in mitigating risks associated with Meloxicam's supply chain remains to be fully realized.

The export data for Meloxicam reveals a high supplier concentration, with the top five exporters accounting for 92.1% of total exports. UNICHEM LABORATORIES LIMITED alone holds a dominant 71.0% share, amounting to $141.5 million USD. This significant concentration poses a single-source risk, where disruptions affecting these key suppliers could severely impact the global availability of Meloxicam.

The PLI scheme, launched to encourage domestic API production, has seen progress with the establishment of new manufacturing units. However, the scheme's current focus on specific APIs and KSMs may not directly address the supply chain risks associated with Meloxicam. Diversifying the supplier base and enhancing domestic production capabilities for Meloxicam's API and KSMs are crucial steps toward mitigating these risks.

Recent geopolitical events have significantly disrupted global supply chains. The closure of the Strait of Hormuz in February 2026, following military conflicts involving Iran, has halted oil tanker movements and affected the transportation of pharmaceuticals from India. Approximately 3,200 ships are stalled within the Persian Gulf, causing worldwide logistical shortages and rising prices. Additionally, instability in the Red Sea and Suez Canal has forced shipping companies to reroute vessels around Africa's Cape of Good Hope, adding delays and increasing fuel costs.

These disruptions have led to increased transportation costs and extended delivery times for pharmaceuticals, including Meloxicam. The U.S. Food and Drug Administration (FDA) has been actively monitoring these supply chain challenges to prevent and mitigate drug shortages. However, the ongoing geopolitical tensions continue to pose risks to the consistent supply of essential medications.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source, thereby enhancing supply chain resilience.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for Meloxicam's API and KSMs to decrease reliance on imports and mitigate risks associated with international supply disruptions.

• Strengthen Inventory Management: Maintain strategic stockpiles of critical raw materials and finished products to buffer against supply chain interruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain, enabling proactive risk management.

• Collaborate with Regulatory Bodies: Work closely with regulatory agencies like the FDA to stay informed about potential shortages and participate in initiatives aimed at ensuring drug availability.

RISK_LEVEL: HIGH